Drug Delivery Systems Global Market Report 2025

The drug delivery system market size has grown strongly in recent years. It will grow from $41.17 billion in 2024 to $44.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to increasing investments in research and development, a surge in chronic disease prevalence, the expansion of biologics and monoclonal antibodies, rising demand for non-invasive drug delivery methods, and the growing need to enhance patient compliance and adherence.

The drug delivery system market size is expected to see strong growth in the next few years. It will grow to $58.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The projected growth in the forecast period can be attributed to an increased emphasis on personalized medicine, a growing pipeline of complex and sensitive pharmaceuticals, a rising prevalence of rare and orphan diseases, supportive regulatory frameworks for innovative delivery technologies, and an expanding geriatric population. Key trends expected during this period include the advancement of nanotechnology-based drug delivery systems, innovations in controlled-release and sustained-release mechanisms, progress in biologics and biosimilars that require specialized delivery methods, the integration of smart drug delivery devices, and the development of targeted delivery solutions specifically for oncology.

The rising prevalence of respiratory disorders is expected to drive the growth of the drug delivery systems market in the coming years. Respiratory disorders are conditions that disrupt the normal function of the lungs and airways, causing breathing difficulties and reduced oxygen intake. The increase in these disorders is largely due to escalating air pollution, which exposes people to harmful airborne particles and gases that damage lung function and contribute to the onset and progression of respiratory diseases. Drug delivery systems play a vital role in the effective treatment and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis. These systems enable medications to be delivered directly to the lungs, improving therapeutic effectiveness while reducing systemic side effects. For example, in March 2025, the UK Health Security Agency - a government body in the UK - reported that tuberculosis cases in England rose by 13% in 2024, increasing from 4,850 cases in 2023 to 5,480 cases. Consequently, the growing prevalence of respiratory disorders is expected to propel the drug delivery systems market.

Key players in the drug delivery systems market are concentrating on developing advanced solutions like metal-free, multidose nasal spray pumps to enhance user comfort and ease of use. These metal-free, multidose nasal spray pumps are designed to administer multiple medication doses through the nasal route without incorporating any metal parts, ensuring safety and compatibility with various formulations. For example, in January 2023, Aptar Pharma, a pharmaceutical company based in the U.S., introduced the APF Futurity metal-free, multidose nasal spray pump. This device is specifically engineered for delivering nasal saline and similar over-the-counter products, with a strong emphasis on recyclability. It is Aptar Pharma’s first highly recyclable nasal spray pump, earning a Class AA certification from cyclos-HTP for European recycling standards. Constructed entirely from polyolefin materials and free from metal components or recycling contaminants, it facilitates easier recycling and enhances the quality of recycled materials. Incorporating Aptar Pharma’s Advanced Preservative Free technology, this metal-free pump provides precise and consistent dosing with smooth operation, maintaining ease of use and effectiveness.

In January 2024, Kindeva Drug Delivery, a U.S.-based contract development and manufacturing organization, acquired Summit Biosciences Inc. for an undisclosed sum. This acquisition expanded Kindeva’s drug delivery capabilities by adding a new platform. It enables the company to provide biopharmaceutical clients with a broader portfolio of advanced drug-device combination products, including those for pulmonary, injectable, transdermal, and nasal delivery. Summit Biosciences Inc. is a U.S.-based contract development and manufacturing firm specializing in intranasal drug delivery.

Major players in the drug delivery systems market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Tandem Diabetes, Pacira Biosciences, Poseida Therapeutics, Universal Stabilization Technologies Inc., Spectrum Pharmaceuticals Inc., VasoRx Inc.

North America was the largest region in the drug delivery system market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Drug delivery systems are innovative technologies or methods developed to transport therapeutic agents within the body in a controlled and efficient way. These systems are designed to improve treatment effectiveness and safety by controlling the rate, timing, and location of drug release. They help maintain optimal drug concentrations at target sites, minimize side effects, and enhance patient adherence to prescribed treatments.

The primary categories of drug delivery systems include injection-based drug delivery systems, oral drug delivery systems, inhalation or pulmonary drug delivery systems, and transmucosal drug delivery systems. Injection-based drug delivery systems are medical devices used to administer drugs into the body via various injection routes, utilizing tools such as syringes, needles, or auto-injectors for precise and targeted delivery. These systems can be made from different material types, including polymer-based, lipid-based, inorganic, biologics-based, and hybrid drug delivery systems. They are used to treat conditions such as infectious diseases, cancer, eye disorders, urinary diseases, diabetes, central nervous system disorders, and more. Key end-users of these systems include hospitals, pharmaceutical companies, research institutions, homecare providers, and diagnostic laboratories.

The drug delivery systems market research report is one of a series of new reports that provides drug delivery systems market statistics, including drug delivery systems industry global market size, regional shares, competitors with a drug delivery systems market share, detailed drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery systems industry. This drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug delivery systems market consists of sales of implantable devices, targeted delivery carriers, nanoparticle-based systems, and bio adhesive systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.